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ABSTRACT
Long-term function of three-dimensional (3D) tissue constructs depends on adequate vascularization after
implantation. Accordingly, research in tissue engineering has focused on the analysis of angiogenesis. For
this purpose, 2 sophisticated in vivo models (the chorioallantoic membrane and the dorsal skinfold
chamber) have recently been introduced in tissue engineering research, allowing a more detailed analysis
of angiogenic dysfunction and engraftment failure. To achieve vascularization of tissue constructs, several
approaches are currently under investigation. These include the modification of biomaterial properties of
scaffolds and the stimulation of blood vessel development and maturation by different growth factors
using slow-release devices through pre-encapsulated microspheres. Moreover, new microvascular net-
works in tissue substitutes can be engineered by using endothelial cells and stem cells or by creating
arteriovenous shunt loops. Nonetheless, the currently used techniques are not sufficient to induce the
rapid vascularization necessary for an adequate cellular oxygen supply. Thus, future directions of re-
search should focus on the creation of microvascular networks within 3D tissue constructs in vitro before
implantation or by co-stimulation of angiogenesis and parenchymal cell proliferation to engineer the
vascularized tissue substitute in situ.
INTRODUCTION
TISSUE ENGINEERING IS AN EMERGING FIELD OF SCIENCE thatthe National Science Foundation first defined in 1987
as ‘‘an interdisciplinary field that applies the principles of
engineering and the life sciences towards the development
of biological substitutes that restore, maintain or improve
tissue function.’’1 Because the loss or failure of tissue or an
organ is one of the most frequent and expensive problems
in human health care today, it is expected that the devel-
opment of methods to regenerate human tissue or to re-
construct entire organs using tissue engineering will have
an important influence on various medical specialties in the
future.
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Plastic and reconstructive surgery would benefit in par-
ticular from tissue engineering to the extent that the ap-
plication of artificially engineered tissue may be completely
substituted for current clinical techniques such as flap
surgery for the treatment of extensive skin defects and
implantation of foreign materials for breast reconstruction.
First steps toward those novel strategies have already been
taken. Engineered skin and cartilage have recently been
introduced for clinical use.2,3 Several other potential tissue
types for substitutive treatment are currently under investi-
gation, including liver,4,5 bone,6muscle,7 adipose,8,9 and ner-
vous10 tissues.
Engineered cartilage is a relatively simple tissue, be-
cause cartilage is avascular and has a low metabolic de-
mand. In contrast, the engineering of more complex tissues
consisting of large 3D structures remains a critical chal-
lenge. Because the amount of oxygen required for cell
survival is limited to a diffusion distance of approximately
150 to 200 mm from the supplying blood vessel,11,12 long-
term survival and function of such 3-dimensionally con-
structed tissues depend on rapid development of new blood
vessels, which provide nutrients and oxygen to the cells not
only of the margin but also of the center of the tissue grafts.
In fact, the growth of a new microvascular system remains
one of the major limitations in the successful introduction
of tissue engineering products to clinical practice. Ac-
cordingly, the focus of research in tissue engineering has
changed toward the understanding of angiogenesis and new
blood vessel formation.
Angiogenesis is defined as the formation of new capil-
laries from pre-existing blood vessels and represents a
complex dynamic process characterized by a coordinated
sequence of humoral and cellular interactions.13,14 Upon
angiogenic stimulation, vascular endothelial cells are acti-
vated and begin to degrade their surrounding basement
membrane by the expression and release of matrix me-
talloproteinases as indicated by vasodilatation. Then the
endothelial cells migrate into the interstitium, resulting in
the formation of capillary buds and sprouts. Endothelial
cells behind the migrating endothelium of the sprouts pro-
liferate so that the newly developing blood vessel elon-
gates. The stabilization of the new vessel wall requires the
recruitment of other cell types, including smooth muscle
cells, pericytes, and fibroblasts, as well as the production of
extracellular matrix compounds. The interaction of distinct
soluble factors such as cytokines and growth factors tightly
regulates all these steps.15
IN VIVO MODELS TO STUDY ANGIOGENESIS
IN TISSUE ENGINEERING PRODUCTS
To improve current techniques and to develop new stra-
tegies for optimal vascularization of implanted tissue con-
structs, sophisticated experimental models are required that
allow for a detailed analysis of blood vessel ingrowth in
engineered tissue constructs in vivo. Previous studies have
analyzed the process of angiogenesis primarily using in vitro
cell culture experiments and histological examinations of
formalin-fixed tissue. Recently, however, 2 commonly used
in vivo models to study angiogenesis, the chorioallantoic
membrane (CAM) assay and the dorsal skinfold chamber,
have been introduced in the field of tissue engineering.
The CAM assay
The chicken embryo CAM is an extraembryonic mem-
brane that serves as a transient gas exchange surface, similar
to the lung. The allantois of the chicken embryo first appears
at day 3 of incubation and rapidly grows until day 10. The
adjacent mesodermal layers of the chorion and the allantois
fuse to form the CAM, which is characterized by a dense
microvascular network (Fig. 1).16,17 During the first days of
incubation, undifferentiated blood vessels are scattered in
the mesoderm of the CAM. These vessels grow rapidly until
day 8, when some differentiate into capillaries. The ability of
the CAM to support the ingrowth of blood vessels in im-
planted tissue substitutes depends on the day of implanta-
tion, because vascularization increases with expansion and
differentiation of the CAM parallel to the development of
the embryo. Between incubation days 9 and 12, the CAM
reaches its maximum vascularization potential. Afterwards,
blood vessels of the CAM begin to regress until incubation
day 21, when the chick hatches. Thus, implantation studies
using the CAMmodel can be performed between incubation
days 5 and 15 (the first 10 days after implantation).
Embryologists originally developed the CAM assay to
study the developmental potential of embryonic tissue grafts.
During the last decades, this in vivo model has successfully
been used to investigate basic mechanisms of angiogenesis
FIG. 1. High-resolution, epi-illumination in vivo microscopy,
visualizing the microvascular network of the chorioallantoic
membrane at day 14 of incubation, consisting of supplying ar-
terioles (arrow), nutritive capillaries (arrow heads), and draining
venules (double arrows). Scale bar: 2.2mm. Color images avail-
able online at www.liebertpub.com/ten.
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such as migration, proliferation, and differentiation of en-
dothelial cells,18–20 changes of the extracellular matrix,21,22
and the effect of growth factors and angiogenesis inhibitors
on blood vessel development.23–25 Moreover, the CAM is a
suitable model for the assessment of the angiogenic potential
of transplanted benign26 and malignant tissue,27,28 whereby
xenografts from mammalian species can be implanted into
the CAMwithout rejection. This is because the early chicken
embryo lacks a complete immune system. Further advan-
tages of this model include easy preparation of the CAM
vascular network, low costs, and less-severe restrictions on
its use than with mammal models.
Two-dimensionally designed matrix constructs and mesh
networks may be positioned directly onto the CAM to per-
form high-resolution imaging of the vascularization process
(Fig. 2). Engineered constructs with an increased 3D ex-
tension, however, cannot be studied using this approach.
Therefore, Borges et al. have modified the original CAM
assay to a cylinder model.29,30 For this purpose, fertilized
chicken eggs were incubated at 37.88C for 3 days. Then,
the eggs were prepared for implantation of the tissue con-
struct by opening the eggshell in a circular area and re-
moving enough albumen to minimize adhesion of the shell
membrane. After 5 days of reincubation, cultivated human
subcutaneous preadipocytes, which were integrated into a
matrix of fibrin glue, were implanted in a specially de-
signed plastic cylinder filled with cell medium and placed
through the prepared observation window onto the surface
of the CAM. In this way, it was possible to investigate the
early steps of vascularization of the constructs for up to 8
days post-implantation using light microscopic and histo-
logical techniques.29 In a second set of experiments, adult
human dermal microvascular endothelial cell spheroids and
preadipocytes were combined in a fibrin matrix and im-
planted into the CAM.30 This resulted in the formation of a
new capillary network within the tissue construct, consist-
ing of human endothelial cells, which connected to the
CAM vessel system. This finding demonstrates that the co-
transplantation of endothelial cell spheroids with me-
senchymal cells might be a promising new approach to
engineering adequately vascularized tissue constructs with-
out applying exogenous angiogenic growth factors.
In addition to the restriction in use to a period of approx-
imately 10 days, there are some limitations on the applica-
tion of the CAM assay. Native epi-illumination microscopy
is adequate to study blood vessels with a size of more than
10 mm, whereas smaller blood vessels (capillaries after
maturation) are more difficult to visualize. This drawback
can be overcome using intravascular application of a high-
molecular-weight fluorescent marker, which, however, re-
quires sophisticated manual skills. Furthermore, the initial
lack of an immune system may be advantageous for the
study of xenografts but does not allow the assessment of the
material biocompatibility. Finally, using the CAM assay,
FIG. 2. The chorioallantoic membrane model allows the vascularization and engraftment of various biomaterials to be studied.
Implantation of a polyglactin 910 mesh (A) and a hydrogel scaffold (C) at day 7 of incubation induces angiogenesis, resulting in
adequate ingrowth of newly formed blood vessels (arrows) until day 14 of incubation (B, D). Scale bars: A, B¼ 0.9mm; C, D¼ 1.4mm.
Color images available online at www.liebertpub.com/ten.
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one should be aware that it consists of embryonal tissue,
which itself is characterized by a growth factor profile
different from that of adult tissue.
Overall, however, we feel that the CAM must be con-
sidered to be a suitable screening assay that allows for the
study of cell viability, proliferation, and differentiation
within implanted tissue constructs during the early steps of
vascularization (the first 10 days after implantation). The
model enables the investigation of the effect of angiogenic
factors and gene therapy on transplanted cells and of the
distinct vascularization properties of different biomaterials
used for the engineering of tissue constructs.
The dorsal skinfold chamber
Algire first introduced the dorsal skinfold chamber in
mice in 1943.31 During the last 3 decades, it has been
modified and adapted for the use in rats,32 immunocom-
petent mice,33 nude and severe combined immuno-deficient
mice,34,35 and hamsters.36
For surgical preparation, the back of the anesthetized
animal is shaved and depilated. Two symmetrical titanium
frames are implanted on the extended dorsal skinfold so
that they sandwich the double layer of skin. Subsequently,
1 layer of skin is completely removed in a circular area of
approximately 15mm in diameter, and the remaining layers
(consisting of striated skin muscle, subcutaneous tissue, and
skin) are covered with a removable coverslip incorporated
into the observation window of one of the titanium frames.
After the preparation, the animals are allowed to recover
for at least 48 h to exclude changes of the microcirculation
due to anesthesia and surgical trauma.
The major advantage of the dorsal skinfold preparation
is that the microcirculation can be analyzed through the ob-
servation window repetitively in unanesthetized animals over
a period of 3 to 4 weeks (Fig. 3).37 Furthermore, the chamber
model is ideal for transplantation and implantation experi-
ments, because the cover glass of the observation window can
temporarily be removed. The skinfold chamber model has
been used to study angiogenesis within various physiological
tissues38–42 and malignant tumors,43,44 as well as biomater-
ials such as synthetic and biosynthetic vascular grafts45–47
and metallic implants.48–50 Using this model, the quantifi-
cation of the angiogenic process is possible using the com-
bination of epi-illumination multi-fluorescence microscopy
and computer-assisted off-line analysis techniques (Fig. 4–6).
Moreover, cellular and molecular aspects can be assessed,
including leukocyte and platelet adhesion, macrophage acti-
vation, mast cell degranulation, vascular endothelial leakage,
and apoptotic and necrotic cell death.
There are also some limitations in the use of the dorsal
skinfold chamber for studying angiogenesis in tissue en-
gineering constructs. The size of the construct should not
exceed 5mm in diameter (width and length) to adequately
fit within the 11-mm-sized chamber. Moreover, the height
of the construct should be limited to 1mm to ensure ade-
quate closure of the chamber tissue by the cover glass.
Despite these limitations, we feel that the dorsal skinfold
chamber model is an ideal tool for the long-term in vivo
study of blood vessel growth and remodeling in porous
biomedical materials used in the field of tissue engineering.
Druecke et al. used the dorsal skinfold chamber of mice
to study neovascularization and biocompatibility of acel-
lular poly(ether ester) block-copolymer scaffolds of dif-
ferent pore sizes.51 This type of biomaterial can be easily
tailored, is biodegradable, and has been proven to support
ingrowth of different tissues. After implantation of the
scaffolds into the dorsal skinfold chambers, vascularization
of the scaffolds was analyzed over 20 days. The results of
the study showed that pore size influences vessel ingrowth
into poly(ether ester) block-polymer scaffolds, which was
most pronounced in the scaffolds with the largest pores.
This corresponds with what has been reported from new
vessel formation in synthetic vascular graft materials45 and
underlines the importance of the biomaterial properties for
the vascularization process of implanted tissue constructs.
ANGIOGENESIS AND VASCULARIZATION
OF TISSUE ENGINEERING CONSTRUCTS
The angiogenic process is of particular interest if a new
structurally integrated tissue is generated from autologous
FIG. 3. (A) Syrian golden hamster equipped with a dorsal
skinfold chamber (weight*4 g). (B) Overview of the observation
window after the implantation of the chamber into the dorsal
skinfold. Large microvessels (arterioles and venules of the striated
muscle and subcutaneous tissue) can be identified without the use
of high-resolution intravital fluorescence microscopy. (C) In-
travital fluorescence microscopy of the micro-angioarchitecture of
the dorsal skinfold chamber consisting of arterioles (arrow),
parallelly arranged muscle capillaries (arrowheads), and post-
capillary and collecting venules (double arrows). Blue light epi-
illumination with intravascular plasma contrast enhancement by
5% fluorescein isothiocyanate–labeled dextran 150,000 i.v. Scale
bars: A¼ 12.5mm; B¼ 2.5mm; C¼ 105 mm. Color images avail-
able online at www.liebertpub.com/ten.
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cultured cells. For this purpose, a small tissue sample is
taken from the patient, and the cells are then isolated and
expanded in culture. Subsequently, these cells are trans-
ferred into a 3D scaffold, which serves as a template for
new tissue formation. Finally, this tissue construct can be
implanted back into the patient, with the surgical procedure
inducing an inflammatory wound-healing response. This,
together with the hypoxia of the cells seeded onto the im-
plant, stimulates the endogenous release of angiogenic
growth factors, which themselves trigger the ingrowth of
new blood vessels from the surrounding host tissue.
However, although blood vessel ingrowth is often noted in
implanted tissue constructs over time, the vascularization is
too slow or too limited to provide adequate nutrient and
oxygen transport to the transplanted cells. To solve this pro-
blem, several approaches are currently under investigation.
The search for the ideal scaffold
Scaffolds provide a 3D framework for cells to attach to
and on which to proliferate that can be implanted into a
tissue defect site. In general, 2 main types of scaffolds can
be differentiated: synthetically derived polymer scaffolds52
and naturally occurring scaffolds.53
Synthetically derived polymer scaffolds should be bio-
compatible and biodegradable and should ensure an optimal
interaction with endothelial cells to promote angiogenesis.
To develop scaffolds that fulfill these properties, it is of
great importance to investigate how different biomaterials
modulate endothelial cell function. For this purpose, a
variety of endothelial cell culture systems have been es-
tablished during recent years. They allow for the evaluation
of new biomaterials in terms of endothelial cell attach-
ment,54 cytotoxicity,55 growth,56 angiogenesis,57 and gene
regulation.56 Additionally, co-culture systems can be used
to study blood vessel development in tissue constructs on a
higher level of cellular organization, considering the in-
teraction between endothelial cells and other cell types.58,59
In addition to the cellular interaction with biomaterials,
the architecture of the scaffold seems to play an important
role in adequate vascularization. Pinney et al. reported that
the 3D structure of a scaffold in itself can change the an-
giogenic activity of incorporated cells.60 When culturing
fibroblasts on a lactate-glycolate copolymer scaffold to form
a dermal-equivalent tissue, they observed that the cellular
content of vascular endothelial growth factor (VEGF)
messenger ribonucleic acid in these 3D cultures was 22
times greater than that in the same fibroblasts grown as
monolayers. In addition, the pore size of the scaffolds has
been shown to be a critical determinant of blood vessel
ingrowth,51 which is significantly faster in pores with a size
greater than 250 mm than in those less than 250 mm.
FIG. 4. Intravital fluorescence microscopy of an isolated ovarian follicle (A, asterisk) and an endometrial tissue fragment (C, asterisk)
directly after transplantation into the dorsal skinfold chamber of a Syrian golden hamster. After 10 days, the grafts are completely
vascularized exhibiting a dense, glomerular-like network of newly formed microvessels (B, D). Scale bars: A, B¼ 105 mm; C,
D¼ 170 mm.
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Finally, molecular deteriorations that are induced during
the incorporation process of the implant might influence the
ingrowth of blood vessels into scaffolds. This may explain
why currently used biomaterials partly fail to vascularize,
independent of their material properties. Fibronectin, for
example, is the only mammalian adhesion protein that binds
and activates a5b1-integrins, which are known to exert
proangiogenic actions, although Vogel and Baneyx,61 who
investigated the role of this adhesion protein in scaffold
vascularization, could not demonstrate an acceleration or
improvement of implant vascularization but documented an
inhibitory action on the process of new vessel formation.
This inhibition was interpreted as the result of excessive
tension generated by cells in contact with implanted bio-
materials, which may have changed the molecular structure
of fibronectin fibrils, deteriorating their capability to bind
and activate a5b1-integrins.
In addition to synthetically derived polymer scaffolds,
naturally occurring scaffolds composed of extracellular
matrix proteins offer promising alternatives for tissue repair
and regeneration. Important examples are small intestinal
submucosa, acellular dermis, cadaveric fascia, the bladder
acellular matrix graft, and the amniotic membrane.53 These
types of scaffolds have been shown to promote rapid in-
teraction with the surrounding host tissue, to induce the
deposition of cells and additional extracellular matrix, and
to accelerate the process of angiogenesis. These naturally
occurring scaffolds can be processed so that they retain
growth factors,62 glycosaminoglycans,63 and structural ele-
ments such as fibronectin, elastin, and collagen,64,65 which
are important regulatory factors of angiogenesis. For ex-
ample, Pieper et al.66 demonstrated that the attachment of
glycosaminoglycans to collagen matrices preserves porous
FIG. 5. Overview of the observation window of a mouse dorsal
skinfold chamber directly after implantation of a poly(lactide-co-
glycolide) (PLGA) scaffold (A, B) and 10 days later (C, D).
Higher magnification of selected regions of interest in the border
zone of the scaffold (C, D: white frame) at day 10 after im-
plantation demonstrates the formation of new blood vessels
growing into the scaffold biomaterial (E, F). The visualization of
the microcirculation is much more detailed using high-resolution
intravital fluorescence microscopy with intravascular plasma
contrast enhancement by 5% fluorescein isothiocyanate–labeled
dextran 150,000 i.v. (B, D, F) than corresponding images made
under a stereo-microscope (A, C, E). Scale bars: A–D¼ 1.4mm;
E¼ 240 mm; F¼ 105mm. Color images available online at www
.liebertpub.com/ten.
FIG. 6. Epi-illumination in vivo microscopy of a polyglactin
910 mesh 14 days after implantation into the dorsal skinfold
chamber of a Syrian golden hamster (A). Intravital fluorescence
microscopy with intravascular plasma contrast enhancement by
5% fluorescein isothiocyanate–labeled dextran 150,000 i.v. of the
border zone of the mesh (A: white frame) shows the formation of a
dense network of newly formed microvessels entwining the syn-
thetic mesh fibers (B). Scale bars: A¼ 875 mm; B¼ 380 mm. Color
images available online at www.liebertpub.com/ten.
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matrix integrity and promotes blood vessel ingrowth. In
another study, elastic fibers of an extracellular matrix scaf-
fold were shown to act as ‘‘microguides’’ for endothelial
cell and pericyte migration during capillary sprouting.67
However, many questions remain to be answered until
naturally occurring scaffolds can be used for clinically re-
levant tissue engineering, including the immunologic re-
sponse of the host to such implants and the methods to
modify their mechanical and physical properties.68 Thus,
the ideal scaffold, which promotes angiogenesis of en-
gineered tissue sufficiently, has not been determined.
Stimulation of angiogenesis by growth factors
Growth factors play the central regulatory role in the
process of angiogenesis. In recent decades, many of these
factors were identified and are now available in recombinant
forms to support engraftment of tissue engineering products.
These include VEGF, platelet-derived growth factor
(PDGF), and different fibroblast growth factors (FGF-1 and
FGF-2).69
The systemic application of these factors might accel-
erate the ingrowth of blood vessels into implanted tissue
constructs. However, this strategy is limited, because the
inherent instability of many growth factors requires high
levels of protein for a measurable effect in vivo, and the risk
of blood vessel development at distant sites of the body
remains uncontrolled.70
A better alternative seems to be the incorporation of
growth factors into the scaffold biomaterial, which guaran-
tees localized and sustained delivery. This principle has al-
ready been shown to be successful in a rabbit ear ulcermodel,
in which the delivery of FGF-1 through biodegradable fibrin
or collagen scaffolds resulted in an enhanced healing process
of full-thickness skin defects, as indicated by increased an-
giogenesis and enhanced epithelialization.71,72 In general,
there are 2 possibilities to incorporate growth factors into
synthetic scaffolds. It can be done by simply mixing the
growth factor with polymer particles before processing the
polymer into a porous scaffold, resulting in a rapid release of
the growth factor within days to weeks.73 The second ap-
proach involves the pre-encapsulation of growth factors in
microspheres, which are then incorporated into the scaffold,
guaranteeing growth factor release over a longer time
span.74,75 Recently, Richardson et al. combined these 2
approaches to establish a new polymer system that allows for
the delivery of 2 or more growth factors with distinct ki-
netics.76 By using this system, they could demonstrate that
dual delivery of VEGF and PDGF, each with distinct ki-
netics, results in the rapid formation of a mature vascular
network inside polymer scaffolds that had been implanted
into the subcutaneous tissue of rats.
Local release of growth factors may also be achieved by
transplanting fragmented tissue such as omentum. The
omentum contains a large number of microvascular en-
dothelial cells and is composed mainly of adipocytes
that produce an enormously high level of VEGF.77 Co-
transplantation of fragmented omentum with preadipocytes
under the dorsal skin of Wistar rats has been shown to
effectively augment soft tissue by increasing VEGF pro-
duction and capillary growth.77
Finally, blood vessel development might be stimulated
using gene transfer of angiogenic growth factors to the cells
incorporated into the scaffold.78 The idea behind this ap-
proach is to achieve an in vivo controlled release of the
growth factor for a certain period. In the past, the angiogenic
therapy of bone tissue regeneration79 and ischemic dis-
eases80–82 was attempted by applying plasmids carrying
growth factor deoxyribonucleic acid. However, at present
there is no information about the adverse effects of such gene
therapy, and it is impossible to control the level and time
period of gene expression. Thus, the controlled release of
growth factors on the protein level seems safer and clinically
more applicable than the use of gene transfer procedures.83
Engineering vascularized tissue in vitro
A network of newly developed microvessels may be en-
gineered in vitro by seeding scaffolds with endothelial
cells.84,85 After implantation of those tissue constructs, the
endothelial cells should develop interconnections to the
blood vessels of the surrounding tissue, resulting in an
adequate perfusion of the prefabricated microvascular net-
work. By using this method, the period required for the in-
growth of new blood vessels into the center of the scaffold
can be dramatically shortened. However, there remain a
considerable number of unsolved problems to realize this
theoretical approach. Although different seeding methods
for 3D polymeric scaffolds have been established,86–88 it is
unclear whether they can guarantee a homogeneous dis-
tribution of endothelial cells throughout a large tissue con-
struct. Moreover, the seeding of a scaffold with endothelial
cells does not necessarily result in the development of new
blood vessels in vitro, because this process depends on the
coordinated release of a variety of signaling factors such as
VEGF and PDGF and involves other cell types, including
smooth muscle cells and pericytes, which are normally
found under in vivo conditions but not necessarily in vitro.
Thus, further research is needed to improve current cell
culture and seeding techniques for the development of tissue
constructs, which bear their own intrinsic vascular system
before implantation and engraftment. Tremblay et al. have
most recently reported promising results.89 With the use of
endothelialized reconstructed skin in which a network of
human capillary-like structures was spontaneously formed
within the dermis in vitro, they showed successful in-
osculation of the in vitro constructed microvasculature to
host blood vessels in less than 4 days after implantation.89
Induction of vascularization by stem cells
In the near future, the use of autologous stem cell sources
will become of major importance for constructing new
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tissues. Several studies have recently reported the suc-
cessful creation of tissue-engineered vascular grafts with
good long-term function by seeding different grafts with
bone marrow cells and endothelial progenitor cells.90–92
In addition, endothelial progenitor cells from the bone
marrow circulate in the bloodstream and are incorporated
into the vessel wall. In culture, these cells have been shown
to give rise to 3 important blood vessel cell components:
endothelial cells, pericytes, and vascular smooth muscle
cells.93 In vivo, a considerable number of experimental
studies could demonstrate that these progenitor cells are
capable of inducing angiogenesis and vasculogenesis at
sites of critical perfusion and hypoxia, such as myocardial
infarction, stroke, and hind-limb ischemia.94 Progenitor
cell–derived regeneration and repair of ischemic or necrotic
tissue are thought to be due to an enhancement of func-
tional re- or neovascularization.95 Accordingly, the vessel-
forming capacity of stem and progenitor cells may also be
useful to improve survival and function of constructed
tissue substitutes by induction and acceleration of angio-
genesis and maturation of newly formed blood vessels.
Future research that aims at improving angiogenesis in
tissue constructs should thus include the therapeutic use of
endothelial progenitor cells.
Engineering vascularized tissue in vivo
In 1979, Erol and Spira reported a new method to fa-
cilitate engraftment in poorly vascularized tissues.96 For
this purpose, they implanted an arteriovenous shunt loop in
the rat groin. After some days, they observed the devel-
opment of new blood vessels originating from the loop that
could support engraftment of an overlying skin graft. Since
then, a number of other experimental studies have used an
arteriovenous shunt loop as a vascular carrier for pre-
fabricated skin flaps.97–99 The principle of this method is
the induction of angiogenesis by increased shear stress and
wall tension within the loops’ vasculature. It is believed
that these 2 factors disturb the integrity of endothelial and
vascular smooth muscle cells, making them more suscep-
tible to the action of angiogenic growth factors.13
Recently, Mian et al. demonstrated that this approach
can be used to engineer new connective tissue in vivo.100,101
They used a model comprising an arteriovenous shunt loop
sandwiched in artificial dermis and placed in a plastic
growth chamber. After subcutaneous implantation of this
chamber, fibroblast and vascular outgrowth from the ar-
teriovenous shunt resulting in the development of a well-
vascularized mass of mature fibrous tissue was observed.
With the use of this technique, Dolderer et al.9 reported the
in vivo generation of large amounts of vascularized adipose
tissue. An adipofascial tissue flap and a matrix scaffold
were integrated into a growth chamber, which was then
implanted into pigs. After 12 weeks, newly formed adipose
tissue had grown to up to 60% of the chamber volume, and
when this tissue was transferred to another site in the body,
it stayed stable in volume and showed no signs of fibrotic
alteration.9 Thus, this novel approach of in vivo tissue en-
gineering may represent a first step toward the endogenous
production of significant amounts of vascularized adipose
tissue for autologous soft tissue replacement.
CONCLUSION AND PERSPECTIVES
Research on tissue engineering during the last few years
has brought evidence that delayed vascularization or lack of
vascularization is one of the major obstacles to successfully
realizing the clinical use of in vitro engineered tissue and
organ substitutes. The design of the scaffold of the tissue
construct, including nature and texture of the material, may
help to overcome the limitations in new blood vessel in-
growth. A porosity of more than 250 mm seems mandatory
for adequate vascularization. The ideal nature of the ma-
terial, however, has yet to be determined. Furthermore, 3
distinct approaches seem to be most promising in improv-
ing and accelerating vascularization and thus should be
addressed by future research in tissue engineering: (1) the
creation of microvascular networks within 3D tissue con-
structs in vitro with inosculation to the host’s vasculature
after implantation; (2) the co-stimulation of angiogenesis
and parenchymal cell proliferation, for example, with the
use of arteriovenous shunt loops, to engineer the vascu-
larized tissue substitute entirely in situ; and (3) the in-
corporation of progenitor or stem cells, in vivo and in vitro,
to accelerate the formation and maturation of new blood
vessels. These 3 approaches, which must be further tested
in sophisticated in vivo models, may further open the door
to successful clinical use of tissue-engineered products in
organ replacement.
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